COVID-19 (Coronavirus)

Central Vein Sign: A Diagnostic Biomarker in Multiple Sclerosis (CAVS-MS)

Condition: Multiple sclerosis

Eligibility

Key Inclusion Criteria:

  • 18-65 years old
  • Referral to a study academic site for a clinical suspicion of multiple sclerosis
  • Typical symptom onset

Key Exclusion Criteria:

  • Contraindication to magnetic resonance imaging (MRI) studies; metal or metal implants incompatible with MRI
  • Inability to tolerate MRI due to claustrophobia or known excessive movement
  • Contraindication to use of gadolinium containing contrast agents

Study Name

Central Vein Sign: A Diagnostic Biomarker in Multiple Sclerosis (CAVS-MS) (IRB no. 00000956)

Summary

This study is designed to identify individuals with a suspicion of multiple sclerosis (MS) based on medical observation and MRI findings. Recent improvements in MRI technology have enabled the straightforward detection of MS lesions. The purpose of the study is to assess the utility of the central vein sign to diagnose MS to avoid delay in initiating treatment. The central vein sign depicts small veins in the brain around which MS changes are centered. These changes can be seen on MRI as a thin dot or straight line within MRI lesions or plaques.

Participants will undergo MRI scans at 2 timepoints as well as neurological assessments, including reviews of diagnosis, treatment, relapses, lab testing and MRI (if previously done). They will also be asked to complete questionnaires.

Principal Investigator